Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

NCT01095887 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Poor enrollment

Conditions

Kidney Transplant

Interventions

DRUG: Eculizumab

Sponsor

Mayo Clinic

Collaborators

[object Object]